Brief: Unicycive Therapeutics Achieves Study Objective In Oxylanthanum Carbonate Clinical Trial
25/06/2024 12:35
June 25 (Reuters) - Unicycive Therapeutics Inc UNCY.O :
* UNICYCIVE THERAPEUTICS ACHIEVES STUDY OBJECTIVE IN
OXYLANTHANUM
CARBONATE (OLC) PIVOTAL CLINICAL TRIAL
* UNICYCIVE THERAPEUTICS INC: NEW DRUG APPLICATION (NDA)
SUBMISSION ANTICIPATED IN Q3 2024
* UNICYCIVE THERAPEUTICS INC: SUCCESSFULLY ESTABLISHED
FAVORABLE
TOLERABILITY AND SAFETY OF OLC
Source text for Eikon: ID:nGNX7x2XWK
Further company coverage: UNCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss